I can understand the concern around the sample size but its double blind study so thats expected. Im guessing they will be seeking partnership with a few companies to fund more trials and same time seek FDA to get more people in USA into further paid trials. It is still part of journey but easily a takeover target before it get to mid journey.
Sit back and enjoy the ride.